Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.364
J. Pereira, R. Mateus, S. Pires, S. Sernache, H. Gonçalves, A. Gouveia
{"title":"NP-017 Risk assessment of occupational exposure to cytotoxic drugs in an outpatient hospital pharmacy","authors":"J. Pereira, R. Mateus, S. Pires, S. Sernache, H. Gonçalves, A. Gouveia","doi":"10.1136/EJHPHARM-2021-EAHPCONF.364","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.364","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84629437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.321
G. Rigueiro, D. Mendes, J. Abrantes, AF Pais, A. Penedones, C. Alves, F. Batel-Marques
{"title":"5PSQ-202 Biosimilars in the real world: results from an active pharmacovigilance programme in a Portuguese oncology hospital","authors":"G. Rigueiro, D. Mendes, J. Abrantes, AF Pais, A. Penedones, C. Alves, F. Batel-Marques","doi":"10.1136/EJHPHARM-2021-EAHPCONF.321","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.321","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89704572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.95
E. Murrja, A. Simonini, G. Ortenzi, R. Sentinelli, A. Garzone, E. Andresciani, S. Pelliccioni, A. Pompilio
Background and importanceKawasaki disease (KD) is a systemic vasculitis of unknown aetiology that affects children younger than 5 years old The SARS-CoV-2 COVID pandemic highlighted cases reported to have an association between SARS-CoV-2 infection and KD Clinical analogies verified between the two conditions open new perspectives with regard to aetiopathogenesis Aim and objectivesTo describe a severe hyperinflammation case of a 9-year-old girl (27 kg,131 cm), previously healthy (mother tested positive for SARS-CoV-2;symptoms of high fever, diarrhoea, headache, abdominal pain), with clinical data regarding the association of SARS-CoV-2 infection and KD Material and methodsIn collaboration with the clinician, we reviewed a medical chart of a KD SARS-CoV-2 associated case, diagnosed between January and July 2020 ResultsOn 16 April 2020, a 9-year-old girl was admitted to the emergency department for suspicion of acute abdomen with an associated persistent fever Nasopharyngeal swab and bronchoalveolar lavage tests for SARS-CoV-2 were negative Abdominal ECO showed lymphadenomegaly due to hyperinflammation and CT scan reported evidence of interstitial, parenchymal thickening and pulmonary infiltration Echocardiogram showed normal coronary arteries with minimal pericardial effusion Broad spectrum empirical antibiotics were started On 18 April (illness day 7) respiratory distress appeared, a critical condition similar to a shock syndrome and multiorgan failure occurred Respiratory support and ionotropic agents were started in the intensive care unit The diagnostic suspicion of atypical incomplete KD, non-coronary involvement, was confirmed and treatment was switched to intravenous immunoglobulin 2 g/kg/day, acetylsalicylic acid 30 mg/kg/day and methylprednisolone infusion until the day of discharge On illness day 10, laboratory blood tests showed progressive reduction in inflammation markers and rapid normalisation of liver enzymes (lipase 1824, amylase 502, declining leucocytes 8 57, Hb 12, negative CRP) Because of the uncertainty about the cause, anti-S-specific IgG antibodies to SARS-CoV-2 were measured Serology testing for SARS-Cov-2 revealed IgG antibody concentrations On day 12 of the illness, she was discharged Conclusion and relevanceIt is known that SARS-CoV-2 infection can activate uncontrolled inflammation Cases are being informally reported among paediatricians, and recently patients with severe forms have been reported, emphasising the apparent rise in the number of children presenting with a multisystem inflammatory state requiring intensive care The connection between viral infections and KD, the analogies between the two conditions, open new perspectives with regard to aetiopathogenesis References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"4CPS-263 Case report of Kawasaki disease and SARS-CoV-2 infection in a paediatric hospital","authors":"E. Murrja, A. Simonini, G. Ortenzi, R. Sentinelli, A. Garzone, E. Andresciani, S. Pelliccioni, A. Pompilio","doi":"10.1136/EJHPHARM-2021-EAHPCONF.95","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.95","url":null,"abstract":"Background and importanceKawasaki disease (KD) is a systemic vasculitis of unknown aetiology that affects children younger than 5 years old The SARS-CoV-2 COVID pandemic highlighted cases reported to have an association between SARS-CoV-2 infection and KD Clinical analogies verified between the two conditions open new perspectives with regard to aetiopathogenesis Aim and objectivesTo describe a severe hyperinflammation case of a 9-year-old girl (27 kg,131 cm), previously healthy (mother tested positive for SARS-CoV-2;symptoms of high fever, diarrhoea, headache, abdominal pain), with clinical data regarding the association of SARS-CoV-2 infection and KD Material and methodsIn collaboration with the clinician, we reviewed a medical chart of a KD SARS-CoV-2 associated case, diagnosed between January and July 2020 ResultsOn 16 April 2020, a 9-year-old girl was admitted to the emergency department for suspicion of acute abdomen with an associated persistent fever Nasopharyngeal swab and bronchoalveolar lavage tests for SARS-CoV-2 were negative Abdominal ECO showed lymphadenomegaly due to hyperinflammation and CT scan reported evidence of interstitial, parenchymal thickening and pulmonary infiltration Echocardiogram showed normal coronary arteries with minimal pericardial effusion Broad spectrum empirical antibiotics were started On 18 April (illness day 7) respiratory distress appeared, a critical condition similar to a shock syndrome and multiorgan failure occurred Respiratory support and ionotropic agents were started in the intensive care unit The diagnostic suspicion of atypical incomplete KD, non-coronary involvement, was confirmed and treatment was switched to intravenous immunoglobulin 2 g/kg/day, acetylsalicylic acid 30 mg/kg/day and methylprednisolone infusion until the day of discharge On illness day 10, laboratory blood tests showed progressive reduction in inflammation markers and rapid normalisation of liver enzymes (lipase 1824, amylase 502, declining leucocytes 8 57, Hb 12, negative CRP) Because of the uncertainty about the cause, anti-S-specific IgG antibodies to SARS-CoV-2 were measured Serology testing for SARS-Cov-2 revealed IgG antibody concentrations On day 12 of the illness, she was discharged Conclusion and relevanceIt is known that SARS-CoV-2 infection can activate uncontrolled inflammation Cases are being informally reported among paediatricians, and recently patients with severe forms have been reported, emphasising the apparent rise in the number of children presenting with a multisystem inflammatory state requiring intensive care The connection between viral infections and KD, the analogies between the two conditions, open new perspectives with regard to aetiopathogenesis References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88099743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.11
S. González, S. V. Blanco, L. H. Poch, JC De Miguel Bouzas, JM Castro Domínguez, L. V. Blanco
{"title":"1ISG-030 Economic impact of biological medicines on a third level hospital","authors":"S. González, S. V. Blanco, L. H. Poch, JC De Miguel Bouzas, JM Castro Domínguez, L. V. Blanco","doi":"10.1136/EJHPHARM-2021-EAHPCONF.11","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.11","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87491992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.27
R. Petti, F. Urso, E. Pasut, D. Tarantino, M. Pani
{"title":"2SPD-044 DruGhost: web based platform of drug unavailability","authors":"R. Petti, F. Urso, E. Pasut, D. Tarantino, M. Pani","doi":"10.1136/EJHPHARM-2021-EAHPCONF.27","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.27","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78872604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.34
G. Loeuille, J. Vigneron, E. D’huart, A. Charmillon, B. Demoré
{"title":"3PC-059 Physicochemical stability of ceftolozane/tazobactam in polypropylene syringes at 61.5/31.25 mg/mL and in elastomeric devices at 25.0/12.5 mg/mL","authors":"G. Loeuille, J. Vigneron, E. D’huart, A. Charmillon, B. Demoré","doi":"10.1136/EJHPHARM-2021-EAHPCONF.34","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.34","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79925270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.21
M. Silva, M. Morgado, O. Fonseca
{"title":"2SPD-038 Bevacizumab versus ranibizumab in ophthalmology outpatient surgery","authors":"M. Silva, M. Morgado, O. Fonseca","doi":"10.1136/EJHPHARM-2021-EAHPCONF.21","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.21","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88751706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.184
D. V. D. Nat, M. Taks, V. Huiskes, B. V. D. Bemt, H. V. Onzenoort
{"title":"4CPS-352 Patients in charge: why we should implement an online personal health record as a tool for medication reconciliation","authors":"D. V. D. Nat, M. Taks, V. Huiskes, B. V. D. Bemt, H. V. Onzenoort","doi":"10.1136/EJHPHARM-2021-EAHPCONF.184","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.184","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85733777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.55
M. Solana, C. M. Dominguez, R. B. Marqués, J. A. Villafranca, Michael Rodriguez, B. Goitia
{"title":"4CPS-223 Real world experience of selexipag for pulmonary arterial hypertension","authors":"M. Solana, C. M. Dominguez, R. B. Marqués, J. A. Villafranca, Michael Rodriguez, B. Goitia","doi":"10.1136/EJHPHARM-2021-EAHPCONF.55","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.55","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90904881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.178
L. Chebrek, C. Jonneaux, V. Dehondt, P. Guillain
{"title":"4CPS-346 Evaluation of the implementation of ‘inhaler interviews’ during medication reconciliation in the pneumology service","authors":"L. Chebrek, C. Jonneaux, V. Dehondt, P. Guillain","doi":"10.1136/EJHPHARM-2021-EAHPCONF.178","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.178","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84258096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：